Switching from GLP-1 injection to pill: what to know

Write down what is pushing the change: needle fatigue, injection-site reactions, supply issues, travel, cost, or privacy. Note what matters most to you, like steady appetite control, fewer stomach side effects, or simpler dosing. Bring a short history of what you have tried and what you tolerated. This helps your prescriber match the option to your goals instead of guessing.

As of the publish date, two options matter most for weight management conversations: Wegovy pill (oral semaglutide 25 mg) and Foundayo (orforglipron). Wegovy pill was FDA approved in Dec 2025 and launched in Jan 2026. Foundayo was FDA approved Apr 1, 2026 and launched Apr 6, 2026. Be cautious with any online “retatrutide” or other peptide products sold as pills or drops, since retatrutide is not approved and anything sold under that name online is unapproved and not legally prescribable outside trials.

The routine may change more than you expect. Wegovy pill must be taken first thing in the morning with a small sip of water, at least 30 minutes before food, drinks, or other oral medicines. Foundayo is a once-daily pill with no fasting or water restrictions and can be taken any time of day. If you take morning medications, supplements, coffee, or breakfast soon after waking, tell your prescriber and pharmacist so they can help you think through a realistic routine.

Even when two medicines target GLP-1, your body can respond differently to a new form or molecule. Keep a simple 1–2 week log of nausea, reflux, constipation/diarrhea, appetite, and energy, plus when you take the pill. Bring that log to follow-ups so your clinician can see patterns. If you have severe or worsening symptoms, contact your prescribing team promptly rather than trying to self-manage changes.

Where you fill it may change when you switch to a pill. Foundayo is available via LillyDirect, telehealth, and retail pharmacies, and at the time of writing the self-pay price started at $149/month for the lowest dose, with a commercial savings card as low as $25/month for eligible patients. Prices and programs change often, so confirm current pricing and eligibility directly with the manufacturer, your plan, or your pharmacist. You can also check TrumpRx.gov, which lists the lowest manufacturer self-pay prices and routes you to the maker’s channel (it is not insurance).

Starting July 1, 2026, CMS has a temporary Medicare GLP-1 Bridge demonstration through Dec 31, 2027. Eligible Part D enrollees pay a $50/month copay (it does not count toward the deductible or out-of-pocket maximum) and it covers Wegovy (all forms), Foundayo, and Zepbound KwikPen, with prior authorization. Eligibility generally requires age 18+ and BMI criteria (BMI ≥35; or ≥30 with certain heart, kidney, or blood-pressure conditions; or ≥27 with prediabetes, prior stroke/heart attack, or symptomatic PAD). People with type 2 diabetes or moderate-to-severe sleep apnea are generally covered through regular Part D instead, so ask your plan which pathway applies to you.